[1] Mehta RL et al. Acute Kidney Injury
Network: report of an initiative to improve outcomes in acute kidney
injury. Critical Care11 (2): R31, 2007.
[2] Lameire N, Van Biesen W,
Vanholder R. Acute kidney injury. Lancet 372:1863-1865, 2008.
[3] Bellomo R et al. Acute
renal failure - definition, outcome measures, animal models, fluid therapy and
information technology needs: the Second International Consensus Conference of
the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care
8 (4): R204–12, 2004.
[4] Kellum JA. Defining and classifying AKI: one set of criteria. Nephrol Dial
Transplant 23: 1471–1472, 2008.
[5] Murray PT. A framework and key research questions in AKI diagnosis and staging in different environments. Clin J Am Soc Nephrol 3: 864-868,
2008.
[6] The Merck Manual.
[7] Ibid.
[8] Naicker S et al. Epidemiology of acute kidney injury in
Africa. Seminars in Nephrology, 28(4):348-353,
2008.
[9] Ibid.
[10] Wyatt CM, Arons RR, Klotman
PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk
factors and impact on in-hospital mortality. AIDS. 20:561-5, 2006.
[11] Choi
AI et al. Long-term clinical consequences of acute kidney injury in the
HIV-infected. Kidney
Int. 78(5):478-85, 2010.
[12] Pakasa NM. Acute tubular
necrosis, acute renal failure and unusual histologic stigmata of acute malaria
in HIV/AIDS patients from the democratic Republic of Congo. Saudi J Kidney Dis
Transpl; 21:153-4, 2010. Available from: http://www.sjkdt.org/text.asp?2010/21/1/153/58793
[13] Naicker,S et al op cit.
[14] McCullough CE. `Nephrology`
in Handbook of HIV Medicine, 2nd Edition. D Wilson et al. Oxford
University Press, 2008
[15] Foley RJ et al.
Amphetamine-induced acute renal failure. Southern Medical Journal,
77(2):258-261, 1984.
[16]De
Vriese AS et al. Rifampicin-associated acute renal failure:
pathophysiologic, immunologic, and clinical features. Am J
Kidney Dis. 31(1):108-15, 1998.
[17] Couzigou
C et al. Urolithiasis in HIV-positive
patients treated with atazanavir. Clin Infect Dis 45(8):e105-8,
2007.
[18] Chan-Tack KM et al. Atazanavir-associated nephrolithiasis: cases from the US
Food and Drug Administration’s adverse event reporting system. AIDS
21: 1215-1218, 2007.
[19] Mills
A et al. Safety and immunovirological activity of once daily maraviroc (MVC)
in combination with ritonavir-boosted atazanavir (ATV/r) compared to
emtricitabine 200mg/tenofovir 300mg QD (TDF/FTC) + ATV/r in treatment-naive
patients infected with CCR5-tropic HIV-1 (Study A4001078): a week 24 planned
interim analysis. Eighteenth International AIDS Conference, Vienna,
abstract THLBB203, 2010.
[20] Diaz F et al.
Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient
with AIDS and Toxoplasma enphalitis. Ann Phamacother 30:41, 1996.
[21] Brigden
D, Whiteman
P. The clinical pharmacology of acyclovir and its prodrugs. Scand
J Infect Dis Suppl. 47:33-9, 1985.
[22] The Merck Manual.
[23] Rodriguez-Iturbe B, Musser
JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol; 19(10):1855-64, 2008.
[24] Zegers RH, Weigl A, Steptoe
A. The death of Wolfgang Amadeus Mozart: an epidemiologic perspective. Ann Intern Med 151(4):274-8, W96-7, 2009.
[25] Naicker S et al.
2008, op cit..
[26] Mishra SK, Das BS. Malaria and acute kidney injury. Seminars in Nephrology, 28(4):395-408,
2008.
[27] Kanodia KV, Shah PR,
Vanikar AV, Kasat P, Gumber M, Trivedi HL. Malaria induced acute renal failure:
A single center experience. Saudi J Kidney Dis Transpl 21:1088-91, 2010.
Available online at http://www.sjkdt.org/text.asp?2010/21/6/1088/72296.
[28] Naicker S et al.2008, op cit.
[29] Kamya MR et al. Effect of HIV-1
infection on malaria treatment outcome in Uganda: a population‐based study. J Infect Dis 193:9-15, 2005.
[30] Pakasa NM, op cit.
[31] Nyimi ML, Lepira FB,
Sumaili KE, Ebengo BC, Nseka MN, Longo-Mbenza B. Acute renal failure associated
with HIV infection. A report of 24 cases. Louvain Medical 120:167-72, 2001.
[32] Pakasa NM, op cit.
[33] Al-Salam S et al. Acute
kidney injury secondary to renal large B-cell lymphoma: role of early renal
biopsy. International Urology and Nephrology, 2010.
[34] McCullough, 2008, op cit.
[35] Ozdamar SO,
Gucer S,
Tinaztepe K.
Hepatitis-B virus associated nephropathies: a
clinicopathological study in 14 children. Pediatr
Nephrol 18(1):23-8, 2003.
[36] Naicker, op cit.
[37] Fine DM, Fogo AB, Alpers
CE. Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient. Seminars in Nephrology 28(6):556-562, 2008.
[38] Brecher
ME, Hay
SN, Park YA. Is it HIV TTP or HIV-associated thrombotic microangiopathy? J Clin Apher 23(6):186-90, 2008.
[39] Benjamin
M et al. Frequency and significance of HIV infection among patients diagnosed
with thrombotic thrombocytopenic purpura. Clin Infect Dis. 48(8):1129-37, 2009.
[40] Becker S
et al. HIV-associated thrombotic microangiopathy in the era of highly active
antiretroviral therapy: an observational study. Clin Infect
Dis 39 Suppl 5:S267-75, 2004.
[41] Ibid.
[42] Ahmed
S et al. HIV associated thrombotic microangiopathy. Postgrad Med J 2002;78:520-524
[43] Furlan M, et al. Von Willebrand factor-cleaving
protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic
syndrome. N Engl J Med 1998;339:1578-84.
[44] Tsai HM, Lian
ECY. Antibodies to von Willebrand
factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585-94, 1998.
[45] George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 354:1927-35, 2006.
[46] Gunther K, Garizio D,
Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human
immunodeficiency virus–related thrombotic thrombocytopenic purpura. Transfusion
47(9):1710-1716, 2007.
[47] Moake JL. Thrombotic
microangiopathies. N Engl J Med 347: 589–600, 2002.
[48] Alpers CE. Light at the end of the TUNEL: HIV-associated
thrombotic microangiopathy. Kidney Int 63:385-96, 2003.
[49] del Arco A et al. Thrombotic thrombocytopenic
purpura associated with human immunodeficiency virus infection: demonstration
of p24 antigen in endothelial cells. Clin Infect Dis 17:360-3, 1993.
[50] Hymes KB, Karpatikin
S. Human immunodeficiency virus
infection and thrombotic microangiopathy. Semin Hematol 34:117-25, 1997.
[51] Becker, op cit.
[52] Novitzky N et al.
Thrombotic thrombocytopenic purpura in patients with retroviral infection is
highly responsive to plasma infusion therapy. British
Journal of Haematology. 128(3):373–379, 2005. Online: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05325.x/full
[53] Ibid.
[54] Jehle AW et al. Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis.
Clinical Infectious Diseases 38:e32-e35, 2004
[55] Naicker et al, op cit.
[56] Rabie H et al. Important HIV-associated
conditions in HIV-infected infants and children. SA Fam Pract 49(4) 22, 2007.
[57] Kirsztajn GM, Suassuna JHR,
Bastos MG. Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B. Kidney Int 76:462-463, 2009.
[58] National Collaborating Centre
for Chronic Conditions. Chronic kidney
disease: national clinical guideline for early identification and management in
adults in primary and secondary care. London: Royal College of
Physicians, 2008.
[59] Schiffrin
EL, Lipman, ML,
Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation 116:85-97, 2007.
[60] Baigent
C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal
failure. Lancet 356:147-52, 2000.
[61] Sarnak
MJ et al. Kidney disease as a risk factor for development of cardiovascular
disease: a statement from the American Heart Association Councils on Kidney in
Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and
Epidemiology and Prevention. Circulation 108:2154-69, 2003.
[62] Brosius
FC III et al. Detection of chronic kidney disease in patients with or at
increased risk of cardiovascular disease: a science advisory from the American
Heart Association Kidney and Cardiovascular Disease Council; the Councils on
High Blood Pressure Research, Cardiovascular Disease in the Young, and
Epidemiology and Prevention; and the Quality of Care and Outcomes Research
Interdisciplinary Working Group: developed in collaboration with the National
Kidney Foundation. Circulation 114:1083-7, 2006.
[63] Go
AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the
risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-305, 2004.
[64] Brugts JJ, Knetsch AM, Mattace-Raso FUS, Hofman A,
Witteman JCM. Renal function and risk of myocardial infarction in an elderly
population: the Rotterdam study. Arch Intern Med 165:2659-65, 2005.
[65] Meisinger C, Doring A, Lowel H, for the KORA Study
Group. Chronic kidney disease and risk of incident myocardial infarction and
all-cause and cardiovascular disease mortality in middle-aged men and women
from the general population. Eur Heart J; 27:1245-50.
[66] an
Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The
glomerular filtration rate in an apparently healthy population and its relation
with cardiovascular mortality during 10 years. Eur Heart J 28:478-83, 2007.
[67] Di
Angelantonio E et al. Chronic kidney disease and risk of major cardiovascular disease and
non-vascular mortality: prospective population based cohort study. BMJ
341:c4986, 2010. Online: http://www.bmj.com/content/341/bmj.c4986.full.
[68] Dhingra
R, Gaziano
JM, Djoussé
L.
Chronic kidney disease and the risk of heart failure
in men.
Circ Heart
Fail. 2011 [Epub ahead of print].
[69] Chronic Kidney Disease
Prognosis Consortium. Association of estimated glomerular filtration rate and
albuminuria with all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis. Lancet 375: 2073–81, 2010.
[70] Choi AI
et al. Association between kidney function and albuminuria with cardiovascular
events in HIV-infected persons. Circulation.
121(5):651-8, 2010.
[71] Mulenga LB et al. Baseline
renal insufficiency and risk of death among HIV-infected adults on
antiretroviral therapy in Lusaka, Zambia. AIDS 22: 1821-1827, 2008.
[72] Choi AI et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
Clinical Infectious Diseases 45:1633–9, 2007.
[73] Gupta SK et al. Guidelines
for the management of chronic kidney disease in HIV-infected patients:
recommendations of the HIV Medicine Association of the Infectious Diseases
Society of America. Clin Infect Dis 40: 1559-1585, 2005.
[74] Mocroft A et al. Chronic
renal failure among HIV-1-infected patients. AIDS 21: 1119-1127, 2007.
[75] Fernando SK et al.
Prevalence of chronic kidney disease in an urban HIV infected population. Am J
Med Sci 335: 89-94, 2008.
[76] Wyatt CM et al. Chronic
kidney disease in HIV infection: an urban epidemic. AIDS 21: 2101-2103, 2007.
[77] Cheung CY et al. Prevalence
of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial
Transplant 22: 3186-3190, 2007.
[78] Naicker S, op cit.
[79] Ibid.
[80] Lucas GM et al.Chronic kidney disease incidence and progression
of ESRD in HIV-infected individuals: a tale of 2 races. J Infect
Dis. 197: 1548-1557, 2008.
[81] Han TM et al. A cross-sectional
study of HIV-seropositive patients with varying degrees of proteinuria in South
Africa. Kidney Int 69: 2243-2250, 2006.
[82] Fabian J et al. Urinary
screening abnormalities in antiretroviral-naive HIV-infected outpatients and
implications for management: a single-center study in South Africa. Ethn Dis
19: S1-80-5. 2009.
[83] Gerntholtz TE et al.
HIV-related nephropathy: a South African perspective. Kidney Int. 69:
1885-1891, 2006.
[84] Fabian J, Naicker S. HIV
and kidney disease in sub-Saharan Africa. Nat Rev Nephrol 5: 591-598, 2009.
[85] Behar DM et al. Absence of
HIV-Associated nephropathy in Ethiopians. American
Journal of Kidney Diseases 47(1):88-94, 2006.
[86] Kopp JB et al. MYH9 is a major-eVect risk gene for
focal segmental glomerulosclerosis. Nat Genet 40:1175–1184, 2008
[87] Oleksyk TK et al. Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa. PLoS ONE 5(7): e11474, 2010.
[88] Tzur S, Rosset S et al.
Missense mutations in the APOL1 gene are highly associated with end stage
kidney disease risk previously attributed to the MYH9 gene. Hum Genet
128:345–350, 2010.
[89] Genovese G et al. Association of trypanolytic ApoL1
variants with kidney disease in African Americans. Science. 329(5993):841-5, 2010.
[90] Tzur S, Rosset S et al.
Missense mutations in the APOL1 gene are highly associated with end stage
kidney disease risk previously attributed to the MYH9 gene. Hum Genet
128:345–350, 2010.
[91] Naicker, S. Burden of
end-stage renal disease in sub-Saharan Africa, op cit.
[92] Wearne, op cit.
[93] Mayosi
BM et al. The burden of non-communicable diseases in South Africa, The Lancet 374(9693): 934 - 947,
2009.
[94] Mulenga LB et al. Baseline
renal insufficiency and risk of death among HIV-infected adults on
antiretroviral therapy in Lusaka, Zambia. AIDS 22: 1821-1827, 2008.
[95] Reid A et al. Severe renal
dysfunction and risk factors associated with renal impairment in HIV-infected
adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46:
1271-1281, 2008.
[96] Wools-Kaloustian K et al.
Renal disease in an antiretroviral-naive HIV-infected outpatient population in
Western Kenya. Nephrol Dial Transplant 22: 2208-2212, 2007.
[97] Andia I et al. Prevalence
Of renal disease In patients attending the HIV/AIDS clinic, at Mbarara
University Teaching Hospital. Third International AIDS Society Conference on
HIV Pathogenesis and Treatment, Rio de Janeiro, Abstract TuPe15.3C02, 2005.
[98] Emem CP et al. Renal disease
in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical
features and risk factors. Nephrol Dial Transplant 23: 741-746, 2008.
[99] Mortier E et al. Urinary pH
in HIV-infected adults in Ivory Coast and in France. AIDS 17: 2003-2005, 2003.
[100] Janabi MY. Renal
abnormalities associated with human immunodeficiency virus infection among
police officers in Dar-es-Salaam, Tanzania. Fourteenth International AIDS
Conference, Barcelona, Abstract ThPeB7197, 2002.
[101] Selik RM, Byers RH Jr, Dworkin
MS. Trends in diseases reported on U.S. death certificates that mentioned HIV
infection, 1987–1999. J Acquir Immune Defic Syndr 29:378–87, 2002.
[102] National
Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Am J
Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
[103] Gill G.V. A sub-Saharan
African perspective of diabetes. Diabetologia.
52(1):8-16, 2009.
[104] ibid.
[105] Mbanya JCN et al. Diabetes in sub-Saharan Africa. Lancet 375(9733):2254 - 2266, 2010.
[106] Choudhury
D, Tuncel M, Levi M. Diabetic nephropathy — a multifaceted target of new therapies. Discovery Medicine, 2010.
http://www.discoverymedicine.com/Devasmita-Choudhury/2010/11/12/diabetic-nephropathy-a-multifaceted-target-of-new-therapies/
[107] Dalla Vestra M, Saller A,
Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2
diabetic nephropathy. Diabetes Matabol 26(Suppl)4:8-14, 2000.
[108]
Brown TT et al. Antiretroviral therapy
and the prevalence and incidence of diabetes mellitus in the multicenter AIDS
cohort study. Arch Intern Med 165: 1179-1184, 2005.
[109]
De Wit S et al. Relationship between use of stavudine and diabetes mellitus.
Eighth International Congress on Drug Therapy in HIV Infection, Glasgow.
Abstract PL9.5. 2006.
[110] Tien
PC et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in
the Women's Interagency HIV Study. AIDS 21(13): 1739-1745, 2007.
[111] Manuthu
EM et al. Prevalence of dyslipidemia and dysglycaemia in HIV infected
patients. East Afr
Med J. 85(1):10-7, 2008.
[112] Choudhury
D (2010), op cit.
[113] Saito
A et al. Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Int J Nephrol. 2011. Online:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005801/?tool=pubmed
[114] Choudhury
D (2010), op cit.
[115] Mathenge W, Foster A, Kuper
H. Urbanization, ethnicity and cardiovascular risk in a population in
transition in Nakuru, Kenya: a population-based survey. BMC Public
Health 10:569, 2010. http://www.biomedcentral.com/1471-2458/10/569
[116] Stewart S et al. Standing at the crossroads between new and historically prevalent
heart disease: effects of migration and socio-economic factors in the Heart of
Soweto cohort study. European
Heart Journal, 2010. Online at:
http://eurheartj.oxfordjournals.org/content/early/2010/12/15/eurheartj.ehq439.long
[117] Maseko
MJ Global cardiovascular risk profiles of untreated hypertensives in an urban,
developing community in Africa. Cardiovasc J Afr 21, 2010.
[118] Kopple
JD. Obesity and chronic kidney disease. J Ren Nutr 20(5
Suppl):S29-30, 2010
[119] Mathenge W, Foster A, Kuper
H. Urbanization, ethnicity and cardiovascular risk in a population in
transition in Nakuru, Kenya: a population-based survey. BMC Public
Health 10:569, 2010. http://www.biomedcentral.com/1471-2458/10/569
[120] Poulter NR et al: The Kenyan
Luo migration study: observations on the initiation of a rise in blood
pressure. BMJ 300(6730):967-972, 1990.
[121] Naicker S (2008), op cit.
[122] Arogundade FA, Barsoum RS.
CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental,
and community support. AmJ Kidney Dis. 2008; 51: 515-523.
[123] Seaberg EC et al. Association between highly active
antiretroviral therapy and hypertension in a large cohort of men followed from
1984 to 2003. AIDS 19: 953-960, 2005.
[124] Baekken M,
Os I,
Sandvik L,
Oektedalen O.
Hypertension in an urban HIV-positive population compared with the general
population: influence of combination antiretroviral therapy. J Hypertens.
26(11):2126-33, 2008.
[125] Jung O et al. Hypertension in HIV-1-infected patients and
its impact on renal and cardiovascular integrity. Nephrol Dial Transplant
19: 2250-2258, 2004.
[126] Bernardino de
la Serna JI et al. Hypertension, HIV infection, and highly active
antiretroviral therapy. [Article in Spanish]
Enferm Infecc
Microbiol Clin. 28(1):32-7, 2010.
[127] Johnston CI
et al. Mechanism of progression of renal disease: current hemodynamic concepts.
J Hypertens
Suppl. 16(4):S3-7, 1998.
[128] Lopez-Novoa. Etiopathology
of chronic tubular, glomerular and renovascular nephropathies: clinical
implications. Journal of Translational Medicine 9:13, 2011.
[129] Naicker S (2008), op cit.
[130] Rao TK et al. Associated
focal and semental glomerulosclerosis in the acquired immunodeficiency syndrome.
N Engl J Med 310; 669-673, 1984.
[131] Carbone
L et al. Course and prognosis of human immunodeficiency virus-associated
nephropathy. Am J Med 1989, 87:389–395.
[132] Wearne, op cit.
[133] USRDS. US Renal Data System
1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases, 1999.
[134] Ahuja TS et al.Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol. 19: 655-659, 1999.
[135] Shaninian V al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected
patients. Am J Kid Dis. 35:884-888, 2000.
[136] Wearne, op cit.
[137] Röling J et
al. HIV-Associated renal diseases and Highly Active Antiretroviral
Therapy–induced nephropathy. Clinical Infectious Diseases 42:1488–95, 2006.
[138] Wearne, op cit.
[139] Lucas GM et al. Highly active antiretroviral therapy and the incidence of
HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541-546,
2004.
[140] Estrella M et al. HIV type 1 RNA level as a clinical indicator
of renal pathology in HIV-infected patients. Clin Infect Dis 43: 377-380,
2006.
[141] Schwartz EJ et al. Highly active antiretroviral therapy and the
epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16: 2412-2420,
2005.
[142] U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United States.
National Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2010.
[143] Naicker S (2008), op cit.
[144] McCullough CE (2008), op cit.
[145] Röling, op cit.
[146] Mocroft A et al. Chronic renal failure among HIV-1-infected
patients. AIDS 21: 1119-1127, 2007.
[147] Fernando SK et al. Prevalence of chronic kidney disease in an
urban HIV infected population. Am J Med Sci 335: 89-94, 2008.
[148] Wyatt CM et al. The impact of hepatitis C virus coinfection
on HIV-related kidney disease: a systematic review and meta-analysis. AIDS
22: 1799-1807, 2008.
[149] Izzedine H et al. Kidney diseases in HIV/HCV-co-infected
patients. AIDS 23: 1219-1226, 2009.
[150] Fischer MJ et al. Hepatitis C and the risk of kidney disease
and mortality in veterans with HIV. J Acquir Immune Defic Syndr 53:
222-226, 2010.
[151] Post
FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Nephrol Dial
Transplant 25: 2178–2187, 2010.
[152] Woodward CL et al.
Tenofovir-associated renal and bone toxicity. HIV Med 10:482–487, 2009.
[153] Wever K et al. Incomplete reversibility of
tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic
Syndr 55(1):78-81, 2010.
[154]
Mocroft A et al. Estimated glomerular
filtration rate, chronic kidney disease and antiretroviral drug use in
HIV-positive patients. AIDS 24: 1667-1678, 2010.
[155]
Cooper RD et al. Systematic review and
meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected
patients. Clin Infect Dis 51: 496-505, 2010.
[156] Cooper
RD et al. Systematic review and
meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected
patients. Clin Infect Dis 51: 496-505, 2010.
[157] Campbell LJ et al. Spectrum of chronic kidney disease in
HIV-infected patients. HIV Med 10: 329-336, 2009.
[158] Arribas JR et al. Tenofovir disoproxil fumarate, emtricitabine,
and efavirenz compared with zidovudine/lamivudine and efavirenz in
treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr
47: 74-78, 2008.
[159] Winston A et al. Minor changes in calculated creatinine
clearance and anion-gap are associated with tenofovir disoproxil
fumarate-containing highly active antiretroviral therapy. HIV Med 7:
105-111, 2006.
[160] Gallant JE et al. Efficacy and safety of tenofovir DF vs
stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized
trial. JAMA 292: 191-201, 2004.
[161] Gupta SK et al. Guidelines for the management of chronic
kidney disease in HIV-infected patients: recommendations of the HIV Medicine
Association of the Infectious Diseases Society of America. Clin Infect Dis
40: 1559-1585, 2005.
[162] Mulenga LB et al. Baseline renal insufficiency and risk of
death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.
AIDS 22(14): 1821-1827, 2008.
[163] Ibid.
[164] Ibid.
[165] World Health Organization. Antiretroviral therapy for HIV infection in
adults and adolescents: recommendations for a public health approach, 2010
revision. Geneva, 2010.
[166] Post, op cit.
[167] Post, op cit.
[168] Kalayjian RC et al. Suppression of HIV-1 replication by
antiretroviral therapy improves renal function in persons with low CD4 cell
counts and chronic kidney disease. AIDS 22: 481-487, 2008.
[169] Peters JP et al. Antiretroviral therapy improves renal
function among HIV-infected Ugandans. Kidney Int 74: 925-929, 2008.
[170] Reid A. Severe renal dysfunction and risk factors
associated with renal impairment in HIV-infected adults in Africa initiating
antiretroviral therapy. Clin Infect Dis 46: 1271-1281, 2008.